



FOR IMMEDIATE RELEASE

May 10, 2010 -- Verrow Pharmaceuticals, Inc., Presents Findings at International Cyclodextrin Symposium

VIENNA, AUSTRIA -- Verrow Pharmaceuticals, Inc., presented its kidney-protection technology at the 15th International Cyclodextrin Symposium. The presentation, titled Nephroprotective Effects of Substituted Cyclodextrins, was given by Chief Science Officer Gerold Mosher, Ph.D.

Verrow's kidney technology utilizes a previously unknown property of certain substituted cyclodextrins to prevent kidney impairment in the presence of several classes of pharmaceuticals and diagnostic agents. Cyclodextrins have typically been used as additives in some drug products to enhance the solubility or stability of the drug, and were believed to have no biological activity.

Dr. Mosher hopes to contribute to others' research into cyclodextrins, but he also hopes to ignite interest in studying the kidney-protective activity that Verrow is developing into several proprietary drugs. The mechanism of kidney protection could lead to more breakthroughs in treating kidney disease, which plays a major supporting role in heart disease and diabetes, among others.

ABOUT VERROW

The company's lead product, Veropaque, is a kidney safe X-ray dye for use in diagnostic and interventional cardiology procedures. Cardiology patients are often at high risk for kidney damage due to obesity, diabetes, and advanced age. Kidney damage from X-ray dyes is responsible for a 3 to 5 times increase in mortality rates.

Verrow Pharmaceuticals, Inc. (www.Verrow.com), a drug development company founded in 2006, is building a portfolio of products based on proven drugs by reformulating them to be less toxic, utilizing a proprietary platform technology.